High Intensity Focused Ultrasound — CPB 0766 | AETNA Coverage Update

Aetna modified CPB 0766 covering HIFU (high intensity focused ultrasound), effective November 15, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its HIFU coverage policy under CPB 0766 to confirm one covered indication — radio-recurrent prostate cancer billed under CPT 55880 — while designating 50 other indications as experimental, investigational, or unproven. If your team bills CPT 0950T, HCPCS C9734, or CPT 61715 for any of those excluded indications, expect claim denial. This update matters most to urology, oncology, and neurology billing teams heading into 2026.

Quick-Reference Table

Aetna HIFU Coverage Criteria and Medical Necessity Requirements 2025

The Aetna HIFU coverage policy under CPB 0766 is narrow. Aetna considers HIFU medically necessary for exactly one indication: radio-recurrent prostate cancer in the absence of metastatic disease.

That's the full covered universe. No other indication clears the medical necessity bar under this policy.

The covered procedure code is CPT 55880 — ablation of malignant prostate tissue, transrectal, with HIFU. If your team bills CPT 55880 with a diagnosis of radio-recurrent prostate cancer and no evidence of metastatic disease, you're in the covered lane. Everything else is out.

Aetna's CPB 0766 Aetna system policy doesn't explicitly state prior authorization requirements in the published bulletin, but don't assume that means prior auth isn't required. Prior authorization rules vary by plan. Check the member's specific plan benefit structure before scheduling the procedure — not after.

For reimbursement on CPT 55880, your documentation needs to clearly support the radio-recurrent designation and the absence of metastases. A claim denial on this code almost always traces back to a diagnosis coding mismatch or insufficient clinical documentation. Get the physician's notes in order before you submit.

Aetna HIFU Exclusions and Non-Covered Indications

This is where CPB 0766 gets long — and where most billing errors will happen.

Aetna considers HIFU experimental, investigational, or unproven for 50 distinct indications. That list spans everything from uterine fibroids to Alzheimer's disease to metastatic bone pain. The breadth signals that Aetna sees limited clinical evidence across nearly every HIFU application outside radio-recurrent prostate cancer.

The real issue here is that HIFU technology is being studied and used clinically for many of these conditions. Physicians may believe a treatment is appropriate. Aetna's coverage policy says otherwise. That gap is where billing teams get caught — a claim goes out, it hits the wall, and the denial takes weeks to resolve.

A few exclusions deserve extra attention because they're areas where HIFU use is growing:

If you treat any of these conditions and a provider is exploring HIFU, talk to your compliance officer before submitting claims. The experimental designation means no path to coverage, and appeals on experimental/investigational denials are difficult to win.

Coverage Indications at a Glance

Aetna HIFU Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for HIFU Under CPB 0766

Covered CPT Codes (When Selection Criteria Are Met)

Not Covered / Experimental Codes

Key ICD-10-CM Diagnosis Codes Referenced in CPB 0766

These codes appear in the policy as associated diagnoses for the non-covered indications. Seeing these codes paired with HIFU procedure codes is a denial signal.

The full ICD-10 code list in CPB 0766 runs to 403 codes. The codes above represent the primary diagnostic categories. For the complete list, review the full policy at the Aetna CPB 0766 source directly.